No definition available.
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
520210 |
1. Apply sex-specific ruleNone |
520210 |
2. Check conditionsNone |
520210 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
219 |
4. Check minimum number of eventsNone |
219 |
5. Include endpointsNone |
219 |
6. Filter based on genotype QC (FinnGen only) |
219 |
Control definitions (FinnGen only)
Controls for this endpoint are individuals that are not cases.
Extra metadata
- Level in the ICD hierarchy
- 3
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- D33
- Name in latin
- Neoplasma benignum cerebri non specificatum
Similar endpoints
↥List of similar endpoints to
Benign neoplasm: Brain, unspecified
based on the number of shared cases.
Similar with more cases:
- Benign neoplasm: Brain, unspecified
- Benign neoplasm of brain and other parts of central nervous system
- Benign neoplasm of brain and other parts of central nervous system
- Benign neoplasms
- Benign neoplasms
Similar with less cases:
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 2424 | 1453 | 938 |
| Only index persons | 1513 | 913 | 600 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.04 | 0.04 | 0.03 |
| Only index persons | 0.03 | 0.03 | 0.02 |
| Median age at first event (years) | |||
| Whole population | 48.74 | 51.26 | 44.54 |
| Only index persons | 42.00 | 45.00 | 37.43 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 219 | 137 | 82 |
| Unadjusted period prevalence (%) | 0.04 | 0.05 | 0.04 |
| Median age at first event (years) | 41.78 | 41.18 | 42.78 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS (R11)
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 203
- Matched controls
- 2031
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
D33.2
ICD-10 Finland
Benign neoplasm: Brain, unspecified
+∞
104.4
91
*
22500
ICD-8 Finland
Benign neoplasm of brain and other parts of nervous system, Brain
+∞
72.3
65
*
2250A
ICD-9 Finland
Benign neoplasm of brain and other parts of nervous system, Brain
+∞
57.0
52
*
AA1CG
NOMESCO Finland
Extensive MRI examination of brain with high intensity magnet
13.3
37.4
70
77
9530/0-C70.0
ICD-O-3
Meningioma, NOS, of cerebral meninges
224.7
37.1
37
*
2152
FHL
Extraction, big brain
+∞
35.5
33
*
111
Kela drug reimbursment
Epilepsy and comparable convulsive disorders
14.9
31.3
54
48
AAB00
NOMESCO Finland
Extirpation of intracranial lesion
38.1
27.9
35
11
D32.00
ICD-10 Finland
Benign tumor of the meninges on the outer surface of the cerebrum
43.4
27.1
33
9
D32.02
ICD-10 Finland
Benign tumor of the meninges at the base of the brain
85.7
21.2
23
*
N03AF01
ATC
carbamazepine; oral, rectal
9.0
18.3
40
54
AAB10
NOMESCO Finland
Partial excision of intracranial lesion
104.3
17.9
19
*
G40.29
ICD-10 Finland
Localization-related (focal)(partial) symptomatic epilepsy and epileptic syndromes with complex partial seizures
28.5
17.3
23
9
2252A
ICD-9 Finland
Benign neoplasm of brain and other parts of nervous system, Cerebral meninges
+∞
16.9
16
*
N03AB02
ATC
phenytoin; systemic
29.0
15.9
21
8
G40.22
ICD-10 Finland
Complex partial epileptic seizure with secondary generalization
23.2
15.0
21
10
N03AF02
ATC
oxcarbazepine; oral
10.0
14.0
28
32
E23.00
ICD-10 Finland
Panhypopituitarism
57.5
14.0
16
*
182
Kela drug reimbursment
Brivaracetam, eslikarbazepin, gabapentin, lacosamide, levetiracetam, perampanel, pregabalin, tiagabin and zonisamide
20.0
13.7
20
11
101
Kela drug reimbursment
Anterior pituitary hypofunction
43.2
13.4
16
*
G40.9
ICD-10 Finland
Epilepsy, unspecified
12.8
13.2
23
20
D35.2
ICD-10 Finland
Benign neoplasm: Pituitary gland
30.7
13.2
17
6
G40.20
ICD-10 Finland
Complex partial seizures with only alteration of consciousness
34.5
12.8
16
5
D33.30
ICD-10 Finland
Acoustic neuroma
40.2
12.4
15
*
AA1DG
NOMESCO Finland
Very extensive MRI examination of brain with high intensity magnet
11.6
11.6
21
20
22520
ICD-8 Finland
Benign neoplasm of brain and other parts of nervous system, Cerebral meninges
+∞
11.6
11
*
D33.00
ICD-10 Finland
Medial pilosytic astrocytoma of the cerebrum
126.8
11.5
12
*
AA1BG
NOMESCO Finland
Standard MRI examination of brain with high intensity magnet
4.9
11.2
38
91
XCK00
NOMESCO Finland
Perimetry
5.8
10.9
31
61
23810
ICD-8 Finland
Neoplasm of unspecified nature of eye, brain and other parts of nervous system, Brain
+∞
10.5
10
*
N03AX14
ATC
levetiracetam; systemic
10.8
9.7
18
18
H02AB09
ATC
hydrocortisone; systemic
10.8
9.7
18
18
G40.19
ICD-10 Finland
Localization-related (focal)(partial) symptomatic epilepsy and epileptic syndromes with simple partial seizures
104.7
9.5
10
*
G40.2
ICD-10 Finland
Localization-related (focal)(partial) symptomatic epilepsy and epileptic syndromes with complex partial seizures
104.7
9.5
10
*
9380/3-C71.9
ICD-O-3
Glioma, malignant of brain, NOS
+∞
9.4
9
*
78020
ICD-8 Finland
Certain symptoms referable to nervous system and special senses, Convulsions
52.3
8.8
10
*
H53.4
ICD-10 Finland
Visual field defects
9.6
8.7
17
19
D32.9
ICD-10 Finland
Benign neoplasm: Meninges, unspecified
28.9
8.6
11
*
2151
FHL
Resection, big brain
+∞
8.4
8
*
H47.2
ICD-10 Finland
Optic atrophy
+∞
8.4
8
*
D32.0
ICD-10 Finland
Benign neoplasm: Cerebral meninges
34.9
8.2
10
*
D32.01
ICD-10 Finland
Benign tumor of meninges on interhemispheric surface
83.0
7.5
8
*
N05BA09
ATC
clobazam; oral
83.0
7.5
8
*
D33.39
ICD-10 Finland
Benign tumor of the cranial nerves UNS
+∞
7.3
7
*
R29.8
ICD-10 Finland
Other and unspecified symptoms and signs involving the nervous and musculoskeletal systems
3.9
7.1
29
84
G93.0
ICD-10 Finland
Cerebral cysts
41.5
6.8
8
*
AA4CG
NOMESCO Finland
Extensive MRI examination of sella turcica with high intensity magnet
23.4
6.7
9
*
D33.02
ICD-10 Finland
Another benign medial tumor of the cerebrum
72.0
6.5
7
*
N03AG01
ATC
valproic acid; systemic, rectal
4.6
6.3
21
50
9161/1-C71.6
ICD-O-3
Hemangioblastoma of cerebellum, NOS
+∞
6.3
6
*
D32.03
ICD-10 Finland
Benign meningioma in ventricles
+∞
6.3
6
*
D32.06
ICD-10 Finland
Benign tumor of the meninges os petrosum or clivus area
+∞
6.3
6
*
183
Kela drug reimbursment
Lamotrigin and topiramate
27.6
6.3
8
*
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
11
12
9.60
9.05
1.5
1.4
—
—
—
0
0
115
816
1.86
4.86
7.0
6.9
1.2
1.2
mmol/l
0.04
103
693
133
1009
1.81
4.33
5.2
5.0
6.5
6.7
mmol/l
0.32
128
937
104
750
1.74
3.90
6.2
6.0
1.2
1.2
mmol/l
0.16
99
682
35
183
2.09
3.54
8.5
9.5
2.1
1.1
mmol/l
1.04
27
151
6
9
6.81
2.88
1.0
1.6
—
—
—
0
0
22
105
2.22
2.80
4.9
7.6
1.3
1.5
%
0.63
22
105
21
104
2.13
2.45
5.1
7.9
0.7
0.7
%
0.19
21
104
20
98
2.15
2.40
5.0
4.8
24.1
24.5
mmol/l
0.23
20
98
8
22
3.73
2.39
1.1
1.2
—
—
—
0
0
8
23
3.57
2.29
1.1
1.2
—
—
—
0
0
8
23
3.57
2.29
1.6
1.5
0.2
0.4
nmol/l
—
8
18
7
18
3.98
2.27
1.1
1.1
—
—
—
0
0
6
14
4.37
2.16
1.3
1.4
2.3
1.9
mmol/l
—
6
14
7
20
3.58
2.07
1.1
1.3
—
—
—
0
0
98
779
1.47
2.05
3.6
4.1
—
—
—
0
0
30
181
1.76
2.01
1.7
1.8
—
—
—
0
0
40
262
1.64
2.00
1.7
1.9
—
—
—
0
0
9
33
2.80
1.95
1.4
1.5
—
—
—
0
0
21
114
1.93
1.95
3.7
3.4
79.0
74.9
ng/l
0.15
21
104
47
324
1.57
1.92
1.8
1.7
1439.3
1249.5
nmol/l
0.56
38
248
(3016894) Varicella zoster virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection
5
12
4.24
1.83
1.4
1.3
—
—
—
0
0
31
195
1.69
1.81
4.7
6.5
102.7
104.0
mmol/l
0.57
31
189
23
134
1.80
1.74
2.3
2.6
65.0
63.6
ml/min/173m2
—
10
57
8
173
0.44
1.67
1.9
1.6
—
—
—
0
0
53
388
1.48
1.64
5.5
4.3
1.0
1.0
kg/l
0.03
13
47
150
1324
1.42
1.62
5.4
4.0
14.8
14.7
pmol/l
0.17
138
1197
28
184
1.60
1.40
1.7
1.9
—
—
—
0
0
10
193
0.50
1.37
1.9
1.8
—
—
—
0
0
53
402
1.42
1.36
2.1
2.3
—
—
—
0
0
85
698
1.36
1.36
3.1
2.2
78.3
76.6
nmol/l
0.20
80
618
189
1768
1.50
1.26
20.2
16.0
139.3
139.7
mmol/l
0.99
184
1719
10
50
2.05
1.18
1.0
1.1
—
—
—
0
0
29
202
1.50
1.15
5.1
4.6
34.0
32.2
%
0.37
23
132
189
1779
1.46
1.10
19.9
16.0
4.0
4.0
mmol/l
0.26
184
1728
16
97
1.70
1.10
2.4
3.8
0.9
1.2
mmol/l
—
6
75
5
21
2.41
1.09
1.6
1.4
—
—
—
0
0
51
399
1.36
1.09
1.8
2.0
3.3
3.1
mg/l
0.15
41
359
185
1736
1.42
1.09
16.8
14.0
25.3
21.3
mg/l
0.72
153
1346
66
540
1.32
1.05
3.5
2.4
56.3
54.8
u/l
0.16
60
503
9
46
2.00
1.05
1.2
1.3
—
—
—
0
0
35
459
0.72
1.01
1.9
2.8
331.0
6439.9
umol/l
1.94
29
392
5
23
2.20
0.98
1.2
1.1
—
—
—
0
0
58
475
1.30
0.91
5.7
4.2
0.0
0.0
estimate
0.00
11
173
80
686
1.26
0.88
3.6
3.9
20.3
40.4
ng/l
1.92
60
471
45
364
1.30
0.78
1.7
1.8
462.4
473.5
pmol/l
0.11
34
304
34
267
1.32
0.72
3.0
4.2
0.8
0.8
mmol/l
0.96
34
247
13
86
1.54
0.67
1.9
1.6
—
—
—
0
0
111
1010
1.20
0.65
9.3
9.4
4.4
4.0
e9/l
0.76
98
881
26
200
1.34
0.64
11.4
7.9
—
—
—
0
0
5
29
1.74
0.64
1.0
1.4
—
—
—
0
0
8
50
1.62
0.62
1.6
2.6
—
—
—
0
0
25
194
1.33
0.59
4.5
6.2
1.0
1.0
mmol/l
0.12
25
174
8
53
1.53
0.59
1.3
1.4
—
—
—
0
0
57
493
1.21
0.56
2.6
3.5
1093.3
1393.9
ng/l
0.43
50
416
95
862
1.18
0.56
4.9
3.9
0.0
0.0
estimate
0.00
13
174
11
158
0.68
0.55
1.3
1.8
—
—
—
0
0
77
695
1.17
0.47
5.1
3.9
—
—
—
0
0
7
49
1.44
0.46
1.0
1.1
—
—
—
0
0
94
866
1.15
0.43
6.1
5.1
0.0
0.0
estimate
0.00
13
175
5
31
1.63
0.43
2.6
2.2
—
—
—
0
0
8
57
1.42
0.42
2.8
1.5
—
—
—
0
0
69
623
1.16
0.42
3.5
2.9
—
—
—
0
0
95
878
1.14
0.42
4.9
3.8
0.0
0.0
estimate
0.00
13
168
5
33
1.53
0.41
1.2
1.3
—
—
—
0
0
0
18
0.00
0.40
0.0
1.2
—
—
—
0
0
5
35
1.44
0.39
1.0
1.6
—
—
—
0
0
0
19
0.00
0.39
0.0
1.2
—
—
—
0
0
9
67
1.36
0.38
1.4
2.0
—
—
—
0
0
33
282
1.20
0.38
3.1
2.5
0.3
1.0
e6/l
2.55
16
161
6
42
1.44
0.36
1.5
1.3
—
—
—
0
0
123
1294
0.89
0.35
4.9
4.1
12.0
11.4
mm/h
0.21
117
1189
169
1633
1.15
0.35
14.3
12.8
84.4
81.9
ml/min/173m2
0.77
142
1330
27
316
0.83
0.34
1.3
1.3
74.1
30.4
iu/ml
—
10
109
7
96
0.72
0.31
1.4
2.0
—
—
—
0
0
28
242
1.18
0.30
2.1
2.2
2.2
2.3
g/l
0.88
28
227
27
311
0.85
0.29
1.4
1.3
16.4
10.8
u/ml
0.20
12
130
8
65
1.24
0.27
1.5
1.8
—
—
—
0
0
5
72
0.69
0.26
2.4
2.0
5.0
3.7
mg/l
—
5
55
5
74
0.67
0.26
1.6
1.5
—
—
—
0
0
6
81
0.73
0.24
1.3
1.8
—
—
—
0
0
14
168
0.82
0.23
2.4
3.6
—
—
—
0
0
5
38
1.32
0.23
1.0
1.3
—
—
—
0
0
0
11
0.00
0.21
0.0
1.5
—
25.8
—
0
11
0
12
0.00
0.21
0.0
1.5
—
—
—
0
0
0
12
0.00
0.21
0.0
1.2
—
—
—
0
0
0
12
0.00
0.21
0.0
1.8
—
—
—
0
0
0
12
0.00
0.21
0.0
1.8
—
—
—
0
0
0
12
0.00
0.21
0.0
1.3
—
—
—
0
0
0
12
0.00
0.21
0.0
1.8
—
—
—
0
0
0
12
0.00
0.21
0.0
1.8
—
—
—
0
0
36
327
1.12
0.21
3.0
3.8
17.0
253.5
ng/l
1.69
29
251
10
80
1.26
0.21
2.9
2.4
1.5
1.2
%
—
10
80
0
13
0.00
0.21
0.0
1.4
—
—
—
0
0
0
13
0.00
0.21
0.0
1.2
—
—
—
0
0
0
13
0.00
0.21
0.0
1.2
—
—
—
0
0
0
14
0.00
0.20
0.0
1.0
—
—
—
0
0
0
14
0.00
0.20
0.0
1.7
—
17.0
—
0
14
166
1696
0.91
0.19
4.8
4.4
1.5
1.5
mmol/l
0.00
159
1571
162
1582
1.09
0.19
5.7
5.7
39.5
39.9
mmol/mol
0.18
151
1482
163
1595
1.09
0.17
5.7
4.8
1.6
1.9
mu/l
2.41
148
1447
7
61
1.15
0.17
1.9
2.0
—
—
—
0
0
167
1703
0.92
0.17
4.7
4.5
4.7
4.7
mmol/l
0.25
157
1585
39
421
0.91
0.17
1.3
1.3
0.9
1.5
u/ml
0.47
14
118
5
69
0.72
0.17
3.4
1.8
—
—
—
0
0
29
265
1.11
0.15
3.2
2.7
1.9
3.3
e6/l
0.49
12
145
161
1641
0.93
0.15
4.3
4.0
1.3
1.3
mmol/l
0.66
154
1511
171
1739
0.92
0.15
5.1
4.9
2.8
2.8
mmol/l
0.04
158
1609
41
385
1.08
0.13
1.7
1.8
1.3
1.1
mg/l
0.14
25
302
137
1341
1.06
0.12
8.2
7.3
76.7
76.7
u/l
0.01
131
1258
70
673
1.06
0.12
2.3
1.9
95.3
98.4
pmol/l
0.23
42
342
13
115
1.14
0.11
2.7
3.5
71.5
210.2
ng/l
2.80
13
103
78
755
1.05
0.10
2.7
2.6
125.7
100.4
ug/l
0.75
70
701
5
45
1.11
0.10
1.0
1.3
—
—
—
0
0
5
46
1.09
0.09
1.0
1.7
—
—
—
0
0
13
116
1.13
0.09
2.0
1.5
—
—
—
0
0
5
47
1.07
0.09
1.6
2.0
—
—
—
0
0
5
48
1.04
0.09
1.0
1.7
—
—
—
0
0
156
1582
0.95
0.09
17.1
14.6
39.7
40.2
%
0.34
103
1192
11
97
1.14
0.09
1.1
1.3
—
—
—
0
0
6
56
1.07
0.08
1.5
1.3
—
—
—
0
0
186
1842
1.06
0.08
11.8
10.3
26.0
25.9
u/l
0.04
178
1783
35
333
1.06
0.08
1.2
1.5
—
—
—
0
0
116
1179
0.97
0.06
5.3
3.1
58.7
44.9
u/l
1.10
110
1103
47
455
1.04
0.06
1.7
1.7
1.9
1.4
mmol/l
1.80
42
381
110
1114
0.97
0.04
2.6
3.1
—
—
—
0
0
27
280
0.96
0.03
3.4
2.8
0.8
0.8
ug/l
0.08
21
169
30
290
1.04
0.03
1.7
1.5
—
—
—
0
0
50
490
1.03
0.02
3.8
2.7
0.4
0.3
e6/l
0.10
38
360
10
101
0.99
0.00
1.0
1.0
—
—
—
0
0
166
1659
1.00
0.00
4.8
4.6
5.7
6.0
mmol/l
1.98
156
1524
144
1442
1.00
0.00
18.4
17.3
13.7
13.7
%
0.10
137
1419
37
365
1.02
0.00
4.6
4.1
22.4
21.0
%
0.25
19
167
0
8
0.00
0.00
0.0
2.0
—
—
—
0
0
0
8
0.00
0.00
0.0
1.0
—
9.7
—
0
8
0
8
0.00
0.00
0.0
1.5
—
—
—
0
0
0
8
0.00
0.00
0.0
2.0
—
—
—
0
0
5
56
0.89
0.00
1.2
1.1
—
—
—
0
0
0
8
0.00
0.00
0.0
2.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.7
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
9
94
0.96
0.00
1.2
1.2
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
1745.0
—
0
6
0
7
0.00
0.00
0.0
4.9
—
98.4
—
0
7
0
7
0.00
0.00
0.0
2.1
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
5
50
1.00
0.00
2.0
1.6
—
0.1
—
0
7
(3011547) Coagulation factor VII activity actual/normal in Platelet poor plasma by Coagulation assay
0
5
0.00
0.00
0.0
1.0
—
152.4
—
0
5
(40770918) von Willebrand factor (vWf).activity actual/normal in Platelet poor plasma by Immunoassay
0
6
0.00
0.00
0.0
2.8
—
93.8
—
0
6
0
5
0.00
0.00
0.0
1.0
—
17.5
—
0
5
5
55
0.91
0.00
1.2
1.1
—
—
—
0
0
0
9
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint CD2_BENIGN_BRAIN_NOS and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| CD2_BENIGN_BRAIN_NOS | 1.973 [1.46, 2.67] | < 0.001 |
| Birth year | 0.99 [0.98, 1.0] | 0.021 |
During the follow-up period (1.1.1998 — 31.12.2019), 87 out of 375 females with CD2_BENIGN_BRAIN_NOS died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| CD2_BENIGN_BRAIN_NOS | 1.925 [1.33, 2.79] | < 0.001 |
| Birth year | 0.988 [0.98, 1.0] | 0.015 |
During the follow-up period (1.1.1998 — 31.12.2019), 59 out of 249 males with CD2_BENIGN_BRAIN_NOS died.
Mortality risk
Mortality risk for people of age
years, who have CD2_BENIGN_BRAIN_NOS.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.144% | 0.407% |
| 5 | 1.001% | 2.468% |
| 10 | 2.701% | 5.618% |
| 15 | 4.635% | 10.786% |
| 20 | 7.798% | 17.817% |
Relationships between endpoints
↥Index endpoint: CD2_BENIGN_BRAIN_NOS – Benign neoplasm: Brain, unspecified
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data